Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib/II study of the AIO GI Group

Annals of Oncology

Volumn 19, Issue 8, 2008, Pages 1442-1449

  Arnold, D ^a   Hohler T ^b   Dittrich, C ^c   Lordick, F ^d   Seufferlein, T ^e   Riemann, J ^f   Woll E ^g   Herrmann, T ^h   Zubel, A ⁱ   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ MERCK KGAA   (Germany)

Author keywords

ACRC; Cetuximab; EGFR; First line chemotherapy; FUFOX; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLICULITIS; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROPATHY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SKIN EXFOLIATION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT COMPLIANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 48749119784     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn150     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Collorectal Cancer Collaborative Group. 2nd edition BMJ 2000; 321: 531-535.
3. Toumigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomised GERCOR study. J Clin Oncol 2004; 22: 229-237.
4. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose intusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
5. Punt GJ. Irinotecan or oxallplatin for first-line treatment of advanced colorectal cancer? Ann OnGol 2005; 16: 945-846.
6. Adenis A, Aranda Aguilar E, Robin YM et al. Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial. J Clin Oncol 2005; 23: 236a (Abstr 3630).
7. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
8. Folprecht G, Lutz MP, Schoffski P et al. Cetuximab and irinotecan/ 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456.
9. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocardinoma: Implications for a standardized scoring system. Cancer 2001; 92: 1331-1346,
10. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
11. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-1318.
12. Li S, Schmitz KR, Jeffrey PD et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-311.
13. Peeters M, Raoul J-L, van Laethem J-L et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer Suppl 2005; 3: 188 (Abstr 664).
14. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007; 25: 164S (Abstr 4000).
15. Tabemero J, Van Cutsem E, Diaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232.
16. Bokemeyer C, Staroslawska E, Makhson A et al. Cetuximab plus 5FU/FA/ oxaliplatin (FOLFOX4) in the first-line treatment of metastastic; colorectal cancer (mCRC): A large-scale phase II study, OPUS. Eur J Cancer Suppl 2007; 5: 236 (Abstr 3004).
17. Grothey A, Deschler B, Kroening H et al. Phase III study at bolus 5-fluorouracil (5-FU/tolinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 232 (Abstr 512).
18. Needle MN. Safety experience with IMC-C225, an ant-epidermal growth factor receptor antibody. Semin Oncol 2002; 29: 55-60.
19. Macdonald JS. Toxicity of 5-fluorouracil. Oncology (Williston Park) 1999; 13: 33-34.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Nolting A, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. In Melbohm B (ed): Pharmacokinetics and Pharmacodynamics of Biotech Drugs, edition. Weinheim: Wiley-VCH 2006; 353-371.
22. Tejpar S, Peeters M, Humblet Y et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007; 25: 172S (Abstr 4037).
23. Porschen R, Arkenau HT, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucavorin plus oxaliplatin: A randomized comparison in metastatic colorectal cancer - a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-4223.
24. de Gramont A, Figer A, Seymour M et al, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
25. Goldberg RM, Sargent DJ, Morton RF et al, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol 2004; 22: 23-30.
26. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin OnGol 2005; 23: 1803-1810.
27. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921.
28. Hebbar M, Wacrenier A, Desauw C et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17: 855-857.
29. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol 2008; 19(3): 508-515.
30. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J. Cancer 2007; 96: 1166-1169.
31. Finocchiaro G, Cappuzzo F, Jdnne PA et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2007; 25: 168S (Abstr 4021).
32. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
33. Lièvre A, Bachet J-B, Ychou M et al. KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with cetuximab. AACR Annual Meeting April 14-18, 2007. Los Angeles, CA 2007 (Abstr 5671).
34. Amado RG, Wolf M, Freeman D et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. Eur J Cancer Suppl 2007; 5: 8 (Abstr 7LB).
35. Tabernero J, Cervantes A, Ciardiello F et al. Correlation of efficacy to KRAS status (wt vs. mut) in patients (pts) with metastatic colorectal cancer (mCRC), treated with weekly (q1w) and q2w schedules of cetuximab combined with FOLFIRI. ASCO Gastrointestinal Cancers Symposium January 25-27, 2008. Orlando, FL 2008 (Abstr 435).